By Doug Macron
A court has denied a request by Alnylam Pharmaceuticals and the Max Planck Institute to block efforts by the University of Massachusetts, the Massachusetts Institute of Technology, and the Whitehead Institute for Biomedical Research to prosecute intellectual property at the heart of an ongoing legal battle, according to a court document released this week.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
